BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Prothena Biosciences Limited readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Prothena Biosciences Limited's dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06268886-688@assetmemo.bio
DTSTAMP:20261121T005938Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Moponetug: Phase 2 readout est. (NCT06268886)
DESCRIPTION:Moponetug\, phase 2\, Alzheimer's Disease.\nStudy: Study to Eva
 luate the Efficacy\, Safety\, and Tolerability of an Anti-MTBR Tau Monoclo
 nal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease\n
 Estimated primary completion: 17 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/moponetug#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06268886
URL:https://assetmemo.bio/drug/moponetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174310-1655@assetmemo.bio
DTSTAMP:20261121T005938Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Prasinezumab: Phase 3 readout est. (NCT07174310)
DESCRIPTION:Prasinezumab\, phase 3\, Parkinson's Disease.\nStudy: A Study t
 o Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Par
 ticipants With Early-Stage Parkinson's Disease\nEstimated primary completi
 on: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pra
 sinezumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07174310
URL:https://assetmemo.bio/drug/prasinezumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
